Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990107 | PMC |
| http://dx.doi.org/10.1177/17585732231152537 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Commentary regarding JPUROL-D-24-00367R2 Adherence to follow-up ten years after hypospadias repair.
J Pediatr Urol
January 2025
University of Texas Southwestern, USA. Electronic address:
Navigating "regulatory fog": Challenges to rigorous abortion research after the Dobbs v. Jackson decision.
Contraception
January 2025
Collaborative for Reproductive Equity, Department of Obstetrics and Gynecology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, 1300 University Avenue, Medical Sciences Center 4245 Madison, WI 53706 USA. Electronic address:
In 2022, the United States' Supreme Court ruling in Dobbs v. Jackson Women's Health Organization overturned Roe v. Wade and federal protections for abortion.
View Article and Find Full Text PDFCommentary on "Cross-sectional associations between dietary intake of polyunsaturated fatty acids, physical function, and sarcopenia in community-dwelling older adults".
J Nutr Health Aging
January 2025
Gazi University, School of Medicine, Department of Internal Medicine, Division of Geriatrics, Ankara, Turkey.
Embracing the mental health challenges of uterus transplant candidates.
Acta Obstet Gynecol Scand
January 2025
Division of Transplantation, Department of Surgery, University of Alabama, Birmingham, Alabama, USA.
Uterus transplantation (UTx) has emerged from clinical trials and is expected to become the standard of care for uterine factor infertility. Uterus transplant candidates historically have had to meet strict eligibility criteria to participate in clinical trials. Continued application of psychologic selection criteria from clinical trial may hinder the expansion of UTx.
View Article and Find Full Text PDFPatient perspective: Is intensive screening of women at high risk of breast cancer evidence-based medicine or ?
Womens Health (Lond)
January 2025
Department of Pharmacy Practice, Midwestern University College of Pharmacy, Glendale Campus, Glendale, AZ, USA.
In 2023, a breast cancer risk assessment and a subsequent positive test for the BRCA-2 genetic mutation brought me to the uncomfortable intersection of a longstanding career as an advocate for high-quality medical evidence to support shared patient-provider decision making and a new role as a high-risk patient. My search for studies of available risk-management options revealed that the most commonly recommended approach for women with a ⩾20% lifetime breast cancer risk, intensive screening including annual mammography and/or magnetic resonance imaging beginning at age 25-40 years, was supported only by cancer-detection statistics, with almost no evidence on patient-centered outcomes-mortality, physical and psychological morbidity, or quality of life-compared with standard screening or a surgical alternative, bilateral risk-reducing mastectomy. In this commentary, I explore parallels between the use of the intensive screening protocol and another longstanding women's health recommendation based on limited evidence, the use of hormone therapy (HT) for postmenopausal chronic disease prevention, which was sharply curtailed after the publication of the groundbreaking Women's Health Initiative trial in 2002.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!